Direct answer (40-60 words)
The FDA approved Ozempic (semaglutide) on December 5, 2017 for adults with type 2 diabetes. Wegovy, the higher-dose semaglutide for chronic weight management, was approved June 4, 2021. The oral version, Rybelsus, was approved September 2019. Tirzepatide-based Mounjaro (May 2022) and Zepbound (November 2023) followed.
Table of contents
- The 30-second answer
- The exact FDA approval date for Ozempic
- The discovery story: from Gila monster venom to GLP-1
- The full GLP-1 timeline: 2005 to 2026
- Why Ozempic dominated the market
- The shift from diabetes to weight management
- Approved indications expanded over time
- The compounding shortage and its end
- What's coming next (oral semaglutide for obesity, triple agonists)
- Differences between Ozempic, Wegovy, and Rybelsus
- FAQ
- Footer disclaimers
The exact FDA approval date for Ozempic
December 5, 2017. The FDA approved Novo Nordisk's semaglutide injection (brand name Ozempic) for adults with type 2 diabetes mellitus, intended to improve glycemic control alongside diet and exercise.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Initial approved doses were 0.5 mg and 1.0 mg weekly. The 2.0 mg dose for diabetes was added in March 2022 based on the SUSTAIN FORTE trial.
Ozempic launched commercially in early 2018.
The discovery story: from Gila monster venom to GLP-1
The GLP-1 story starts with the Gila monster, a venomous lizard native to the southwestern United States. In the 1990s, John Eng at the Bronx VA Medical Center isolated a peptide called exendin-4 from Gila monster saliva. Exendin-4 stimulated insulin release, similar to human GLP-1, but was much more resistant to enzymatic degradation. Human GLP-1 has a half-life of 1 to 2 minutes; exendin-4 has a half-life of 2 to 4 hours.
That stability made exendin-4 a viable drug candidate. Synthetic exendin-4 became exenatide, marketed as Byetta, FDA-approved April 28, 2005 by Amylin Pharmaceuticals. Byetta required twice-daily injections.
Liraglutide (Victoza) followed in January 2010, with once-daily dosing and stronger glycemic effect. Liraglutide was modified human GLP-1 with a fatty acid attachment that bound albumin, extending half-life.
Semaglutide came next. Novo Nordisk modified the liraglutide structure with a different fatty acid spacer that bound albumin even more tightly, plus a substituted amino acid resistant to DPP-4 enzyme cleavage. The result: a half-life of about 7 days, enabling once-weekly dosing.
The drug development timeline:
- 2008: Semaglutide first synthesized
- 2012 to 2016: SUSTAIN clinical trial program (10 trials, over 8,000 patients)
- 2017: FDA approval
The progression from twice-daily to weekly dosing transformed GLP-1 medication from a niche diabetes drug into mainstream therapy.
The full GLP-1 timeline: 2005 to 2026
| Date | Drug (brand) | Active ingredient | Indication | Manufacturer |
|---|---|---|---|---|
| April 2005 | Byetta | Exenatide (twice daily) | T2 diabetes | Amylin/Lilly |
| January 2010 | Victoza | Liraglutide (daily) | T2 diabetes | Novo Nordisk |
| January 2012 | Bydureon | Exenatide ER (weekly) | T2 diabetes | Amylin/Lilly |
| April 2014 | Tanzeum | Albiglutide (weekly) | T2 diabetes | GSK (withdrawn 2018) |
| September 2014 | Trulicity | Dulaglutide (weekly) | T2 diabetes | Eli Lilly |
| December 2014 | Saxenda | Liraglutide 3.0 mg (daily) | Chronic weight management | Novo Nordisk |
| December 2017 | Ozempic | Semaglutide (weekly) | T2 diabetes | Novo Nordisk |
| September 2019 | Rybelsus | Semaglutide oral (daily) | T2 diabetes | Novo Nordisk |
| June 2021 | Wegovy | Semaglutide 2.4 mg (weekly) | Chronic weight management | Novo Nordisk |
| May 2022 | Mounjaro | Tirzepatide (weekly) | T2 diabetes | Eli Lilly |
| November 2023 | Zepbound | Tirzepatide (weekly) | Chronic weight management | Eli Lilly |
| 2024 | Wegovy expanded | Semaglutide 2.4 mg | Cardiovascular risk reduction in obesity | Novo Nordisk |
Each approval represented a step forward, either in dosing convenience, efficacy, or indication expansion.
Why Ozempic dominated the market
By 2024, Ozempic became the best-known prescription medication brand in the United States, with name recognition rivaling household over-the-counter products. Several factors explain that dominance:
Once-weekly dosing. Replaced the twice-daily injection burden of Byetta and the daily burden of Victoza. Adherence improved sharply.
Strong glycemic effect. SUSTAIN trial data showed HbA1c reductions of 1.5 to 1.8% at the 1.0 mg dose, larger than most competitors at the time of launch.
Substantial weight loss as side effect. Patients on Ozempic for diabetes were losing 6 to 8% of body weight on average. The off-label weight management interest exploded.
Cardiovascular benefit. SUSTAIN-6 (Marso et al., NEJM 2016) showed semaglutide reduced major cardiovascular events in high-risk T2DM patients. The CV benefit became part of the prescribing case for patients with cardiovascular comorbidities.
Cultural moment. Celebrity disclosure of GLP-1 use, social media discussion, and aggressive direct-to-consumer marketing drove unprecedented patient demand starting in 2022.
The cultural moment created supply constraints that affected both Ozempic and Wegovy through 2023 and most of 2024.
The shift from diabetes to weight management
Ozempic was approved for type 2 diabetes only. Off-label use for weight loss began almost immediately, especially after providers and patients noticed the consistent weight loss in diabetic patients.
Novo Nordisk responded by developing Wegovy, which is the same molecule (semaglutide) at a higher dose (2.4 mg weekly vs Ozempic's 0.5, 1.0, or 2.0 mg). Wegovy was approved in June 2021 for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity.
Wegovy's main approval trial, STEP 1 (Wilding et al., NEJM 2021), showed average weight loss of 14.9% over 68 weeks at 2.4 mg, vs 2.4% on placebo. That was a meaningful result. Previous weight management medications averaged 5 to 8% loss.
The semaglutide story expanded further:
- 2024: Wegovy received approval to reduce cardiovascular risk (heart attack, stroke, cardiovascular death) in adults with cardiovascular disease and obesity, based on the SELECT trial
- 2025: Various ongoing trials in heart failure with preserved ejection fraction, kidney disease, and Alzheimer's disease
- Semaglutide is now thought of as a cardiometabolic drug, not just a diabetes or weight drug
Approved indications expanded over time
Ozempic and the broader semaglutide platform have accumulated indications:
Ozempic (semaglutide for diabetes):
- December 2017: Type 2 diabetes glycemic control
- January 2020: Cardiovascular risk reduction in T2DM with established cardiovascular disease
- March 2022: 2.0 mg dose added for additional glycemic effect
- January 2024: Reduce risk of kidney disease worsening, kidney failure, and cardiovascular death in T2DM with chronic kidney disease
Wegovy (semaglutide 2.4 mg for weight management):
- June 2021: Chronic weight management in adults with obesity or overweight + comorbidity
- December 2022: Adolescents 12 and up
- March 2024: Reduce cardiovascular events in adults with cardiovascular disease and obesity/overweight
Rybelsus (oral semaglutide for diabetes):
- September 2019: Type 2 diabetes glycemic control
- January 2020: 14 mg dose for additional effect
The pattern of expansion shows the maturation of the semaglutide story from a single disease drug into a multi-indication therapy.
The compounding shortage and its end
The FDA placed semaglutide and tirzepatide on the drug shortage list starting in 2022 due to demand outpacing supply. This triggered a provision under federal law (FDCA section 503A and 503B) allowing licensed compounding pharmacies to prepare semaglutide and tirzepatide for individual patient prescriptions during the shortage.
Compounded GLP-1 medications became a significant part of the market between 2022 and 2024, accessible to patients without insurance coverage for the brand-name drugs.
Status as of early 2026:
- Semaglutide was removed from the FDA shortage list in early 2025 after Novo Nordisk increased manufacturing
- Tirzepatide remained on the shortage list longer; its status has been variable
- Compounded semaglutide is still available through 503A pharmacies for patients with documented medical necessity, but the regulatory environment is tightening
- Compounded tirzepatide availability depends on the current FDA shortage designation
Patients should verify that any compounding pharmacy they use is state-licensed and FDA-registered. Quality varies; reputable compounders use USP-grade active pharmaceutical ingredients and certificate-of-analysis documentation.
What's coming next (oral semaglutide for obesity, triple agonists)
The pipeline continues to expand:
Oral semaglutide for obesity. Currently Rybelsus is approved only for diabetes. Novo Nordisk has trials for higher-dose oral semaglutide for weight management. Expected FDA decision in 2026 to 2027.
Retatrutide (Lilly). Triple agonist hitting GLP-1, GIP, and glucagon receptors. Phase 3 trial data expected 2026 to 2027. Early data suggests weight loss of 24% over 48 weeks at the highest dose, exceeding tirzepatide.
CagriSema (Novo Nordisk). Combination of cagrilintide (an amylin analog) with semaglutide. Trials ongoing.
Survodutide (Boehringer Ingelheim). Dual GLP-1/glucagon agonist in late-stage trials.
Orforglipron (Lilly). Oral non-peptide small-molecule GLP-1 agonist. Convenience advantage of pill form without the dietary restrictions of Rybelsus. Phase 3 ongoing.
The next 3 to 5 years will bring meaningful new options to patients. Whether they replace or complement semaglutide and tirzepatide depends on efficacy, tolerability, and price.
Differences between Ozempic, Wegovy, and Rybelsus
All three are semaglutide products from Novo Nordisk. Differences:
| Feature | Ozempic | Wegovy | Rybelsus |
|---|---|---|---|
| Form | Injection | Injection | Oral tablet |
| Frequency | Weekly | Weekly | Daily |
| Doses | 0.25, 0.5, 1.0, 2.0 mg | 0.25, 0.5, 1.0, 1.7, 2.4 mg | 3, 7, 14 mg |
| Indication | T2 diabetes | Weight management, CV risk reduction | T2 diabetes |
| Max weight loss in trials | ~6-8% (off-label) | ~15% (STEP 1) | ~3-5% |
| Insurance coverage | Often covered for diabetes | Variable | Often covered for diabetes |
Ozempic and Wegovy are the same molecule at different doses. The differences are dose, indication, and packaging. Rybelsus is the oral form, with bioavailability around 1% (most of the dose isn't absorbed), so the doses are higher to compensate.
For most patients, the choice is determined by indication and insurance coverage rather than personal preference.
Reasonable internal links
- Does Ozempic Show Up on Blood Work?
- Is Low Blood Pressure a Side Effect of Ozempic?
- Ozempic and Diverticulitis
Why the Ozempic approval date gets confused
Ozempic did not appear all at once as a weight-loss story. Semaglutide moved through diabetes research, Ozempic approval for type 2 diabetes, Wegovy approval for chronic weight management, and then a broader public conversation about GLP-1 medications.
That timeline matters because a search for the Ozempic approval date can mean several different dates: the first semaglutide approval, the Ozempic diabetes label, the Wegovy obesity label, or later cardiovascular and other outcome data.
| Question | What to check | Why it matters |
|---|---|---|
| Ozempic | Type 2 diabetes semaglutide brand | Different from Wegovy |
| Wegovy | Weight-management semaglutide brand | Different dose and indication |
| Public confusion | Ozempic used as shorthand | The brand name often means the whole GLP-1 category |
Helpful next steps on FormBlends
FAQ
When did Ozempic come out?
The FDA approved Ozempic on December 5, 2017 for adults with type 2 diabetes. It launched commercially in early 2018.
When was Ozempic approved for weight loss?
Ozempic itself has never been approved for weight loss. The same molecule, semaglutide, was approved at a higher dose (2.4 mg) under the brand name Wegovy on June 4, 2021 for chronic weight management.
Who makes Ozempic?
Novo Nordisk, a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The drug is manufactured at Novo Nordisk facilities including major sites in Denmark, the United States, and Brazil.
What was the first GLP-1 medication?
Byetta (exenatide), approved April 28, 2005 by Amylin Pharmaceuticals. It was a twice-daily injection derived from the venom of the Gila monster.
Was Ozempic the first weekly GLP-1?
No. Bydureon (exenatide extended-release) was approved in January 2012 as the first weekly GLP-1. Trulicity (dulaglutide) followed in 2014. Ozempic launched in 2017 with stronger glycemic and weight loss effects than its predecessors.
Why does Ozempic seem to be everywhere now if it was approved in 2017?
Awareness exploded between 2021 and 2023, driven by celebrity disclosure, social media, the launch of Wegovy for weight management, and aggressive direct-to-consumer marketing. The medication itself was around for 5 years before becoming a cultural phenomenon.
When did compounded semaglutide become available?
Around 2022, when the FDA placed semaglutide on the drug shortage list, allowing licensed compounding pharmacies to prepare it under federal regulations. The shortage designation for semaglutide was lifted in early 2025, narrowing legitimate compounding access.
What was the original intended use of Ozempic?
Type 2 diabetes glycemic control. The weight loss was an observed side effect that drove the development of Wegovy at a higher dose for weight management.
How long has tirzepatide been available?
Tirzepatide (brand names Mounjaro for diabetes and Zepbound for weight management) was approved May 13, 2022 for type 2 diabetes. The Zepbound version for weight management was approved November 8, 2023.
Has Ozempic always been at the same doses?
No. Original approval was for 0.5 mg and 1.0 mg weekly. The 0.25 mg starting dose was always part of the titration schedule. The 2.0 mg dose was added in March 2022 based on the SUSTAIN FORTE trial showing additional glycemic benefit.
What was the SUSTAIN trial program?
A series of 10 phase 3 trials of semaglutide in type 2 diabetes, conducted between 2012 and 2017, which provided the data for the Ozempic FDA approval. SUSTAIN-6 specifically established cardiovascular safety and benefit. The acronym stands for "Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes."
Will Ozempic still be available in 2030?
Yes, almost certainly. The patent on semaglutide doesn't expire until the early 2030s. Novo Nordisk has continued to expand indications and is investing heavily in manufacturing capacity. Generic and biosimilar versions are likely to follow patent expiration.
How does Ozempic compare to older diabetes medications?
Ozempic offers stronger glycemic effect than most older oral medications (sulfonylureas, DPP-4 inhibitors), causes weight loss (most older medications cause weight gain), reduces cardiovascular events in high-risk patients, and has weekly dosing. The trade-offs are higher cost, GI side effects, and the need for injection (in the Ozempic form).
Author / review note
Reviewed by the FormBlends Medical Team. Primary references: U.S. Food and Drug Administration approval letters and prescribing information for Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Byetta, Victoza, Bydureon, Saxenda, and Trulicity; Marso SP, et al., SUSTAIN-6 (New England Journal of Medicine, 2016); Wilding JPH, et al., STEP 1 (New England Journal of Medicine, 2021); Lincoff AM, et al., SELECT trial (New England Journal of Medicine, 2023); Eng J, et al., original isolation of exendin-4 (Journal of Biological Chemistry, 1992).
Image suggestions
- Hero: Horizontal timeline graphic with all major GLP-1 approvals from 2005 (Byetta) through 2023 (Zepbound), with Ozempic highlighted at December 2017
- Discovery story: Illustration of the Gila monster with a callout about exendin-4 leading to modern GLP-1 medications
- Comparison section: Side-by-side product graphic showing Ozempic, Wegovy, and Rybelsus packaging differences with key spec table
JSON-LD FAQ schema
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro, Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →